Al-Jaouni Rima, Schneider Stephane M, Piche Thierry, Rampal Patrick, Hébuterne Xavier
Am J Gastroenterol. 2002 Nov;97(11):2843-9. doi: 10.1111/j.1572-0241.2002.07032.x.
Patients with Crohn's disease (CD) have increased energy expenditure and fat oxidation. Steroids, commonly used to treat flare-up of CD, induce weight gain. This study was designed to evaluate the effects of prednisone and budesonide on energy expenditure and substrate oxidation in patients with CD.
Twenty-nine women with CD and 10 healthy controls were studied. Ten patients received prednisone (0.75-1.0 mg/kg/day), nine received budesonide (9 mg/ day), and 10 did not receive steroids. Resting energy expenditure and substrate oxidation were measured by indirect calorimetry in a fasting state and after a standard diet.
In the fasting state, resting energy expenditure was higher in patients without steroids than in the controls. Lipid oxidation was lower (p < 0.01) in patients with prednisone (0.46 +/- 0.39 mg/kg/min) than in patients with budesonide (0.97 +/- 0.28 mg/kg/min) and without steroids (1.06 +/- 0.32 mg/kg/min), but was similar with control subjects (0.47 +/- 0.20 mg/kg/min). Postprandially, lipid oxidation was lower (p < 0.01) in patients with prednisone (0.32 +/- 0.23 mg/kg/min) than in patients with budesonide (0.75 +/- 0.20 mg/kg/min), without steroids (0.82 +/- 0.23 mg/kg/min), and controls (0.58 +/- 0.15 mg/kg/min). Protein oxidation was significantly higher in patients with prednisone than in the other subjects.
In women with CD, prednisone decreases lipid oxidation and increases protein oxidation. These effects are not observed with budesonide and may contribute to the weight gain and side effects commonly observed with prednisone. A low-fat/high-protein diet could be proposed during a course of prednisone.
克罗恩病(CD)患者能量消耗增加且脂肪氧化增强。常用于治疗CD病情发作的类固醇会导致体重增加。本研究旨在评估泼尼松和布地奈德对CD患者能量消耗和底物氧化的影响。
对29例CD女性患者和10名健康对照者进行研究。10例患者接受泼尼松(0.75 - 1.0mg/kg/天)治疗,9例接受布地奈德(9mg/天)治疗,10例未接受类固醇治疗。通过间接测热法在禁食状态和标准饮食后测量静息能量消耗和底物氧化。
在禁食状态下,未使用类固醇的患者静息能量消耗高于对照组。泼尼松治疗的患者(0.46±0.39mg/kg/分钟)的脂质氧化低于布地奈德治疗的患者(0.97±0.28mg/kg/分钟)和未使用类固醇的患者(1.06±0.32mg/kg/分钟),但与对照受试者(0.47±0.20mg/kg/分钟)相似。餐后,泼尼松治疗的患者(0.32±0.23mg/kg/分钟)的脂质氧化低于布地奈德治疗的患者(0.75±0.20mg/kg/分钟)、未使用类固醇的患者(0.82±0.23mg/kg/分钟)和对照组(0.58±0.15mg/kg/分钟)。泼尼松治疗的患者蛋白质氧化显著高于其他受试者。
在患有CD的女性中,泼尼松会降低脂质氧化并增加蛋白质氧化。布地奈德未观察到这些作用,这可能是泼尼松常见的体重增加和副作用的原因。在泼尼松治疗期间可建议采用低脂/高蛋白饮食。